Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

The present clinical and laboratory classification criteria for antiphospholipid syndrome
(APS) were established in Sydney, Australia, in 2006. In this review, we focus on the …

Currently, we use the classification criteria for antiphospholipid syndrome (APS) formulated
during the consensus conference in Sapporo and revised in Sydney 1. Classification criteria …

Antibodies against β2 glycoprotein I (anti-β2GPI) have been identified as the main
pathogenic autoantibody subset in anti-phospholipid syndrome (APS); the most relevant …

The primary anti-phospholipid syndrome (APS) is characterized by the production of
antibodies that bind the phospholipid-binding protein β2 glycoprotein I (β2GPI) or that …

Background To date, the exact prevalence of anti-β 2 glycoprotein I domain I (anti-β 2 GPI-
DI) antibodies in patients with antiphospholipid syndrome (APS) and their role when …

Objective To assess the value of a combination of anti–β2‐glycoprotein I (anti‐β2 GPI)
domain I antibody and anti–phosphatidylserine/prothrombin complex (anti‐PS/PT) antibody …

Antiphospholipid Syndrome (APS) is a condition characterized by the occurrence of
thromboembolic events and/or pregnancy loss combined with one laboratory criterion …

Abstract Antiphospholipid syndrome (APS), heparin-induced thrombocytopenia, and
paroxysmal nocturnal hemoglobinuria are 3 acquired thrombophilias that carry a high risk of …

Anti-phospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are
autoimmune diseases characterized by autoantibody production and autoantibody-related …